Article Information
History
- January 25, 2022.
Article Versions
- Version 1 (September 29, 2020 - 15:54).
- Version 2 (October 1, 2020 - 23:18).
- Version 3 (October 3, 2020 - 14:06).
- Version 4 (January 9, 2021 - 17:42).
- You are viewing Version 5, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Xabier García-Albéniz1,2,*,
- Julia del Amo3,
- Rosa Polo3,
- José Miguel Morales-Asencio4 and
- Miguel A Hernán2,5
- 1RTI Health Solutions. Barcelona, Spain
- 2CAUSALab. Harvard T.H. Chan School of Public Health. Boston, MA, USA
- 3National Plan Against AIDS, Ministry of Health. Madrid, Spain
- 4Department of Nursing and Podiatry, Universidad de Málaga, Málaga, Spain
- 5Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Boston, MA, USA
- ↵*Correspondence:
Xabier Garcia-Albeniz. RTI Health Solutions. Av. Diagonal, 605, 9-1. 08028. Barcelona, Spain,xgarcia{at}rti.org
Posted January 25, 2022.
Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19
